vs
Side-by-side financial comparison of KILROY REALTY CORP (KRC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
KILROY REALTY CORP is the larger business by last-quarter revenue ($272.2M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). KILROY REALTY CORP runs the higher net margin — 6.3% vs 1.6%, a 4.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -1.2%).
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
KRC vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $272.2M | $177.4M |
| Net Profit | $17.1M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 6.3% | 1.6% |
| Revenue YoY | -5.0% | 5.0% |
| Net Profit YoY | -73.7% | — |
| EPS (diluted) | $0.11 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $272.2M | $196.9M | ||
| Q3 25 | $279.7M | $179.5M | ||
| Q2 25 | $289.9M | $181.1M | ||
| Q1 25 | $270.8M | $168.9M | ||
| Q4 24 | $286.4M | $187.3M | ||
| Q3 24 | $289.9M | $168.6M | ||
| Q2 24 | $280.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $17.1M | — | ||
| Q3 25 | $162.3M | $5.4M | ||
| Q2 25 | $79.6M | $-4.8M | ||
| Q1 25 | $43.7M | $4.8M | ||
| Q4 24 | $65.0M | — | ||
| Q3 24 | $57.7M | $-143.5M | ||
| Q2 24 | $54.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 6.3% | — | ||
| Q3 25 | 58.0% | 3.0% | ||
| Q2 25 | 27.4% | -2.7% | ||
| Q1 25 | 16.1% | 2.8% | ||
| Q4 24 | 22.7% | — | ||
| Q3 24 | 19.9% | -85.1% | ||
| Q2 24 | 19.4% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.11 | $0.05 | ||
| Q3 25 | $1.31 | $0.12 | ||
| Q2 25 | $0.57 | $-0.11 | ||
| Q1 25 | $0.33 | $0.10 | ||
| Q4 24 | $0.50 | $0.38 | ||
| Q3 24 | $0.44 | $-3.11 | ||
| Q2 24 | $0.41 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $179.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.4B | $653.9M |
| Total Assets | $10.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $179.3M | $238.4M | ||
| Q3 25 | $372.4M | $246.3M | ||
| Q2 25 | $193.1M | $445.9M | ||
| Q1 25 | $146.7M | $493.6M | ||
| Q4 24 | $165.7M | $484.6M | ||
| Q3 24 | $625.4M | $453.8M | ||
| Q2 24 | $835.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $5.4B | $693.1M | ||
| Q3 25 | $5.5B | $727.2M | ||
| Q2 25 | $5.4B | $757.8M | ||
| Q1 25 | $5.4B | $798.5M | ||
| Q4 24 | $5.4B | $778.3M | ||
| Q3 24 | $5.4B | $749.6M | ||
| Q2 24 | $5.4B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $10.9B | $1.3B | ||
| Q3 25 | $11.0B | $1.3B | ||
| Q2 25 | $10.9B | $1.5B | ||
| Q1 25 | $10.9B | $1.6B | ||
| Q4 24 | $10.9B | $1.6B | ||
| Q3 24 | $11.4B | $1.5B | ||
| Q2 24 | $11.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $566.3M | — |
| Free Cash FlowOCF − Capex | $450.3M | — |
| FCF MarginFCF / Revenue | 165.4% | — |
| Capex IntensityCapex / Revenue | 42.6% | — |
| Cash ConversionOCF / Net Profit | 33.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $833.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $566.3M | $43.7M | ||
| Q3 25 | $176.6M | $60.8M | ||
| Q2 25 | $143.7M | $12.0M | ||
| Q1 25 | $136.9M | $35.5M | ||
| Q4 24 | $541.1M | $33.1M | ||
| Q3 24 | $176.3M | $53.9M | ||
| Q2 24 | $88.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $450.3M | $43.5M | ||
| Q3 25 | $148.7M | $57.0M | ||
| Q2 25 | $118.4M | $9.3M | ||
| Q1 25 | $115.6M | $26.9M | ||
| Q4 24 | $440.8M | $31.0M | ||
| Q3 24 | $147.2M | $49.8M | ||
| Q2 24 | $69.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 165.4% | 22.1% | ||
| Q3 25 | 53.1% | 31.7% | ||
| Q2 25 | 40.9% | 5.1% | ||
| Q1 25 | 42.7% | 15.9% | ||
| Q4 24 | 153.9% | 16.6% | ||
| Q3 24 | 50.8% | 29.6% | ||
| Q2 24 | 24.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 42.6% | 0.1% | ||
| Q3 25 | 10.0% | 2.2% | ||
| Q2 25 | 8.7% | 1.5% | ||
| Q1 25 | 7.9% | 5.1% | ||
| Q4 24 | 35.0% | 1.1% | ||
| Q3 24 | 10.1% | 2.4% | ||
| Q2 24 | 6.8% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 33.10× | — | ||
| Q3 25 | 1.09× | 11.20× | ||
| Q2 25 | 1.81× | — | ||
| Q1 25 | 3.13× | 7.37× | ||
| Q4 24 | 8.32× | — | ||
| Q3 24 | 3.06× | — | ||
| Q2 24 | 1.63× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KRC
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
